Overview

Experience

Xi has represented a wide range of multinational companies, Chinese state-owned enterprises and private companies on various aspects of competition law, including handling Chinese and overseas merger and foreign investment filings, responding to investigations and sector inquiries, conducting internal compliance audits, reinforcing compliance programme, mitigating operational risks. Xi has a wealth of experience in various sectors including healthcare, automotive, industrial, FMCG, technology & internet, fund investment, mining, energy, and infrastructure & transport.

 

Xi is qualified in the PRC and the New York State of the US. Prior to joining Zhao Sheng, he worked at two leading international law firms including working at the offices in Brussels and London.

 

Xi is recognised by Legal 500 as a Leading Individual, ranked by Chambers in the China competition/antitrust space and named a “Future Leader – Competition” by Who’s Who Legal. He also won the Best Antitrust Writing Awards by Concurrences.

His representative experience includes advising:

  • CSR Corporation Limited and China CNR Corporation Limited on the multijurisdictional merger filings for their $26 billion merger of equals 

  • China National Nuclear Corporation on the multijurisdictional merger filings for the acquisition of China Nuclear Engineering & Construction Group Corporation Limited 

  • COSCO Shipping Specialized Carriers on the multijurisdictional merger filings for its joint venture with Guangzhou Salvage Bureau under the Ministry of Transport

  • China Merchants Port Holdings on the Chinese merger filing for the acquisition into Liaoning Port Group

  • Jingye Group on the multijurisdictional merger filings for its acquisition of certain assets of British Steel, the UK’s second-largest steelmaker

  • Novozymes on the Chinese merger clearance in relation to its $12.3 billion merger with Chr. Hansen, the largest-ever merger between two Danish companies
  • Rio Tinto on the Chinese merger clearance in relation to its $2 billion joint venture with Baowu

  • Takeda on the Chinese merger clearance in relation to its $62 billion acquisition of Shire, the biggest ever overseas acquisition by a Japanese company

  • SABMiller on the conditional Chinese merger clearance in relation to its £71 billion acquisition by AB InBev

  • Qiagen on the Chinese merger filing for its $12.5 billion contemplated but aborted acquisition by Thermo Fisher Scientific

  • Consortium led by GIP and Meridiam on the Chinese merger clearance for its $15.44 billion acquisition of certain businesses in relation to the Veolia/Suez transaction

  • Bayer on the Chinese merger clearance for its $7.6 billion sale of animal health business to Elanco, creating the world’s second-biggest animal-health company

  • Reckitt Benckiser on the Chinese merger clearance for its $16.6 billion acquisition of Mead Johnson

  • Glencore on the remedy implementation for the conditional Chinese merger clearance in relation to its acquisition of Xstrata

  • A broad range of PE investors in relation to the antitrust and foreign investment matters for their buy-out deals and growth investments in and outside China

Education 

2011 - 2012                New York University School of Law (Vanderbilt Scholar), LL.M

2006 - 2008                Renmin University of China, LL.M

2002 - 2006                Renmin University of China, LL.B

Languages

Mandarin, English